undamentalytics Newsletter
Sign in

AIM Immunotech Inc. balance sheet

At the end of fiscal 2025, AIM Immunotech Inc. had total assets of $5.8m, total liabilities of $15.6m and shareholders' equity of −$9.8m. It held $3.0m in cash against $8.0m of debt: net debt of $5.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents58332122210139322752310
Receivables————————0000—21—0—
Total current assets—37324519171174410405036154310
Total assets—52445832292319141421655840199613
Accounts payable—12212111100006620
Total current liabilities—3513342235111191065
Short-term debt—————————000———244
Long-term debt————————2222———314
Total debt000000002642—00584
Total liabilities—661334———————2910165
Shareholders' equity5946384529252015961361573810−1−108
Net debt (negative = net cash)−58−3−3−2−1−2−2−2053−36−32−27−535−6
Shares outstanding—————————————————29m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AIM vs IBIOAIM vs LSTAAIM vs CLDX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from AIM Immunotech Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to AIM Immunotech Inc.